# US 2025/0376540 A1 · Binding Proteins 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0376540 A1
- Document ID: US20250376540A1
- Status: Published application
- Kind: A1
- Application number: 19/186,381
- Filed: 2025-04-22
- Published: 2025-12-11
- Earliest claimed: 2017-07-17
- Assignees: Nucleus Therapeutics Pty. Ltd; Yale University
- Applicants: Nucleus Therapeutics Pty. Ltd.; Yale University
- Inventors: James Campbell; Valentina Dubljevic; James Hansen; Zahra Rattray; Jiangbing Zhou
- Web page: https://patentgrep.com/patent/US20250376540A1

## CPC

- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61P 35/00: Antineoplastic agents
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 2039/505: {comprising antibodies}
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/77: Internalization into the cell
- C07K 2317/82: functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to cell penetrating anti-DNA binding proteins. Compositions comprising these binding proteins may be may be useful for delivering agents to cells and treating diseases such as cancer.

## Claims

### Claim 1

A cell penetrating anti-DNA binding protein having an antigen binding domain, wherein the antigen binding domain binds to DNA and comprises: a heavy chain variable region (Vu) comprising a sequence as shown in any one of SEQ ID NOs: 17 to 23 and light chain variable region (Vt) comprising a sequence as shown in any one of SEQ ID NOs: 24 to 29.

### Claim 2 (depends on 1)

The binding protein of claim 1, comprising:
a VH having a complementarity determining region (CDR) 1 as shown in SEQ ID NO: 1, a CDR2 as shown in SEQ ID NO: 2 or SEQ ID NO: 3 and a CDR3 as shown in SEQ ID NO: 4; and
a VL having a CDR1 as shown in SEQ ID NO: 5 or SEQ ID NO: 6, a CDR2 as shown in SEQ ID NO: 7 and a CDR3 as shown in SEQ ID NO: 8.

### Claim 3 (depends on 1)

The binding protein of claim 1 comprising:
(i) a VH comprising a sequence as shown in SEQ ID No: 21; and
(ii) a VL comprising a sequence as shown in SEQ ID NO: 27.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 1)

The binding protein of claim 1, which is:
(i) a single chain Fv fragment (scFv);
(ii) a dimeric scFv (di-scFv);
(iii) a trimeric scFv (tri-scFv);
(iv) any one of (i), (ii) or (iii) linked to a constant region of an antibody, Fc or a heavy chain constant domain CH2 and/or CH3.

### Claim 8 (depends on 7)

The binding protein of claim 7, which is a scFv.

### Claim at position 7

-12. (canceled)

### Claim 13 (depends on 1)

The binding protein of claim 1, which is:
(i) a diabody;
(ii) a triabody;
(iii) a tetrabody;
(iv) a Fab;
(v) a F(ab′)2;
(vi) a Fv;
(vii) one of (i) to (vi) linked to a constant region of an antibody, Fc or a heavy chain constant domain CH2 and/or CH3; or,
(viii) an intact antibody.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The binding protein of claim 13, which is an intact antibody.

### Claim 16 (depends on 15)

The binding protein of claim 15, which comprises an amino acid sequence as shown in any one of SEQ ID NOs: 32-47.

### Claim 17 (depends on 1)

The binding protein according to claim 1, which is conjugated to a therapeutic compound.

### Claim 18 (depends on 1)

A nucleic acid encoding the binding protein of claim 1.

### Claim at position 14

-20. (canceled)

### Claim 21 (depends on 1)

A composition comprising the binding protein of claim 1 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 1)

A method of treating cancer in a subject, the method comprising administering to the subject and effective amount of the binding protein of claim 1.

### Claim at position 17

-31. (canceled)

### Claim 32 (depends on 22)

The method according to claim 22, wherein the cancer is colon cancer, brain cancer, prostate, ovarian, breast, endometrial, melanoma, or pancreatic cancer.

### Claim 33 (depends on 22)

The method according to claim 22, wherein the cancer is a triple negative breast cancer.

### Claim 34 (depends on 22)

The method according to claim 22, wherein the cancer is a glioblastoma.

### Claim 35 (depends on 1)

The binding protein according to claim 1, which is conjugated to a nucleic acid.

### Claim 36 (depends on 35)

The binding protein according to claim 35, wherein the binding protein is conjugated to the nucleic acid via a linker cleavable by cathepsin.

### Claim 37 (depends on 17)

The binding protein according to claim 17, wherein the binding protein is conjugated to the therapeutic compound via a linker cleavable by cathepsin.
